0001821825-24-000044.txt : 20240403 0001821825-24-000044.hdr.sgml : 20240403 20240403184043 ACCESSION NUMBER: 0001821825-24-000044 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Weaver Kirke CENTRAL INDEX KEY: 0001959622 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40235 FILM NUMBER: 24820731 MAIL ADDRESS: STREET 1: 30 HUDSON STREET STREET 2: FLOOR 33 CITY: JERSEY CITY STATE: NJ ZIP: 07302 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Organon & Co. CENTRAL INDEX KEY: 0001821825 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464838035 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 30 HUDSON STREET STREET 2: FL 33 CITY: JERSEY CITY STATE: NJ ZIP: 07302 BUSINESS PHONE: 551-430-6000 MAIL ADDRESS: STREET 1: 30 HUDSON STREET STREET 2: FL 33 CITY: JERSEY CITY STATE: NJ ZIP: 07302 4 1 wk-form4_1712184027.xml FORM 4 X0508 4 2024-03-31 0 0001821825 Organon & Co. OGN 0001959622 Weaver Kirke C/O ORGANON & CO. 30 HUDSON STREET, FLOOR 33 JERSEY CITY NJ 07302 0 1 0 0 Gen. Counsel & Corp. Secy. 0 Common Stock 2024-03-31 4 M 0 4294 0 A 22825 D Common Stock 2024-03-31 4 F 0 1224 18.80 D 21601 D Common Stock 2024-03-31 4 M 0 6200 0 A 27801 D Common Stock 2024-03-31 4 F 0 1767 18.80 D 26034 D Common Stock 2024-03-31 4 M 0 3125 0 A 29159 D Common Stock 2024-03-31 4 F 0 891 18.80 D 28268 D Restricted Stock Units 2024-03-31 4 M 0 4294 0 D Common Stock 4294 4294 D Restricted Stock Units 2024-03-31 4 M 0 3125 0 D Common Stock 3125 3125 D Restricted Stock Units 2024-03-31 4 M 0 6200 0 D Common Stock 6200 12400 D Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. The Reporting Person was granted RSUs on November 7, 2022, which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. The Reporting Person was granted RSUs on March 31, 2023. On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. /s/ Tarnetta V. Jones, as Attorney-in-Fact for Kirke Weaver 2024-04-03